Download PDF
Semin Liver Dis 2007; 27(2): 140-151
DOI: 10.1055/s-2007-979467
Copyright © 2007 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

The Impact of Autoimmunity on Hepatocytes

Diego Vergani1 , Giorgina Mieli-Vergani1
  • 1Institute of Liver Studies, King's College London School of Medicine at King's College Hospital, London, United Kingdom
Further Information

Publication History

Publication Date:
22 May 2007 (online)

    Permissions and Reprints

ABSTRACT

In this article, the impact of autoimmunity on the hepatocyte is analyzed in three distinct settings: classical autoimmune hepatitis, chronic hepatitis C virus infection with autoimmune manifestations, and de novo autoimmune hepatitis after liver transplantation. (1) Classical autoimmune hepatitis: Using as model autoimmune hepatitis type 2, whose main autoantigen is known, complementary aspects of the autoimmune response are revisited, including the targeting of discrete antigenic regions by humoral and cellular effectors of damage and a defect in the counterbalancing immunoregulatory mechanisms. (2) Chronic hepatitis C virus infection: This condition provides clues to the possible role of viruses as triggers of autoimmunity. The interaction between hepatitis C virus and its receptor on B lymphocytes is the likely trigger of a polyclonal activation leading to the production of autoantibodies. These appear not to be an epiphenomenon but to be markers of hepatocyte damage. (3) De novo autoimmune hepatitis after liver transplantation: The intriguing observation that autoimmune hepatitis can arise de novo after liver transplantation is presented and its possible pathogenic mechanisms are discussed.

KEYWORDS

Autoimmune hepatitis - T regulatory cells - autoreactive T cells - autoantibodies - hepatitis C virus infection

REFERENCES

  • 1 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology. 1993;  18 998-1005
    CrossrefPubMedGoogle Scholar
  • 2 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31 929-938
    CrossrefPubMedGoogle Scholar
  • 3 Vergani D, Alvarez F, Bianchi F B et al.. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.  J Hepatol. 2004;  41 677-683
    CrossrefPubMedGoogle Scholar
  • 4 Muratori L, Parola M, Ripalti A et al.. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.  Gut. 2000;  46 553-561
    CrossrefPubMedGoogle Scholar
  • 5 Ma Y, Okamoto M, Thomas M G et al.. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.  Hepatology. 2002;  35 658-664
    CrossrefPubMedGoogle Scholar
  • 6 Wen L, Ma Y, Bogdanos D P et al.. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity.  Curr Mol Med. 2001;  1 379-389
    CrossrefPubMedGoogle Scholar
  • 7 Senaldi G, Portmann B, Mowat A P, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis.  Arch Dis Child. 1992;  67 1447-1453
    PubMedGoogle Scholar
  • 8 Weaver C T, Harrington L E, Mangan P R, Gavrieli M, Murphy K M. Th17: an effector CD4 + T cell lineage with regulatory T cell ties.  Immunity. 2006;  24 677-688
    CrossrefPubMedGoogle Scholar
  • 9 Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage.  Nat Med. 2007;  13 139-145
    PubMedGoogle Scholar
  • 10 Nouri-Aria K T, Donaldson P T, Hegarty J E, Eddleston A L, Williams R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis.  J Hepatol. 1985;  1 235-241
    CrossrefPubMedGoogle Scholar
  • 11 Nouri-Aria K T, Hegarty J E, Alexander G J, Eddleston A L, Williams R. Effect of corticosteroids on suppressor-cell activity in “autoimmune” and viral chronic active hepatitis.  N Engl J Med. 1982;  307 1301-1304
    PubMedGoogle Scholar
  • 12 Cortesini R, LeMaoult J, Ciubotariu R, Cortesini N S. CD8 + CD28 - T suppressor cells and the induction of antigen-specific, antigen-presenting cell-mediated suppression of Th reactivity.  Immunol Rev. 2001;  182 201-206
    CrossrefPubMedGoogle Scholar
  • 13 Vento S, Hegarty J E, Bottazzo G, Macchia E, Williams R, Eddleston A L. Antigen specific suppressor cell function in autoimmune chronic active hepatitis.  Lancet. 1984;  1 1200-1204
    PubMedGoogle Scholar
  • 14 Shevach E M, McHugh R S, Piccirillo C A, Thornton A M. Control of T cell activation by CD4 + CD25 + suppressor T cells.  Immunol Rev. 2001;  182 58-67
    CrossrefPubMedGoogle Scholar
  • 15 Longhi M S, Ma Y, Bogdanos D P, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4( + )CD25( + ) regulatory T cells in autoimmune liver disease.  J Hepatol. 2004;  41 31-37
    CrossrefPubMedGoogle Scholar
  • 16 Longhi M S, Hussain M J, Mitry R R et al.. Functional study of CD4 + CD25 + regulatory T cells in health and autoimmune hepatitis.  J Immunol. 2006;  176 4484-4491
    PubMedGoogle Scholar
  • 17 Longhi M S, Ma Y, Mitry R R et al.. Effect of CD4 + CD25 + regulatory T cells on CD8 T cell function in patients with autoimmune hepatitis.  J Autoimmun. 2005;  25 63-71
    PubMedGoogle Scholar
  • 18 Ma Y, Bogdanos D P, Hussain M J et al.. Polyclonal T cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2.  Gastroenterology. 2006;  130 868-882
    CrossrefPubMedGoogle Scholar
  • 19 Lobo-Yeo A, Alviggi L, Mieli-Vergani G, Portmann B, Mowat A P, Vergani D. Preferential activation of helper/inducer T lymphocytes in autoimmune chronic active hepatitis.  Clin Exp Immunol. 1987;  67 95-104
    PubMedGoogle Scholar
  • 20 Wen L, Peakman M, Lobo-Yeo A et al.. T cell-directed hepatocyte damage in autoimmune chronic active hepatitis.  Lancet. 1990;  336 1527-1530
    CrossrefPubMedGoogle Scholar
  • 21 Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders.  Clin Exp Immunol. 1973;  15 331-344
    PubMedGoogle Scholar
  • 22 Alvarez F, Bernard O, Homberg J C, Kreibich G. Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum.  J Exp Med. 1985;  161 1231-1236
    CrossrefPubMedGoogle Scholar
  • 23 Waxman D J, Lapenson D P, Krishnan M, Bernard O, Kreibich G, Alvarez F. Antibodies to liver/kidney microsome1 in chronic active hepatitis recognize specific forms of hepatic cytochrome P-450.  Gastroenterology. 1988;  95 1326-1331
    PubMedGoogle Scholar
  • 24 Zanger U M, Hauri H P, Loeper J, Homberg J C, Meyer U A. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.  Proc Natl Acad Sci USA. 1988;  85 8256-8260
    PubMedGoogle Scholar
  • 25 Gueguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily.  J Exp Med. 1988;  168 801-806
    CrossrefPubMedGoogle Scholar
  • 26 Manns M P, Johnson E F, Griffin K J, Tan E M, Sullivan K F. Major antigen of liver kidney microsomal autoantibodies in idiopathic autoimmune hepatitis is cytochrome P450db1.  J Clin Invest. 1989;  83 1066-1072
    PubMedGoogle Scholar
  • 27 Manns M P, Griffin K J, Sullivan K F, Johnson E F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase.  J Clin Invest. 1991;  88 1370-1378
    PubMedGoogle Scholar
  • 28 Kerkar N, Choudhuri K, Ma Y et al.. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease.  J Immunol. 2003;  170 1481-1489
    PubMedGoogle Scholar
  • 29 Ma Y, Thomas M G, Okamoto M et al.. Key residues of a major cytochrome P4502D6 epitope are located on the surface of the molecule.  J Immunol. 2002;  169 277-285
    PubMedGoogle Scholar
  • 30 Peakman M, Lobo-Yeo A, Mieli-Vergani G, Davies E T, Mowat A P, Vergani D. Characterization of anti-liver kidney microsomal antibody in childhood autoimmune chronic active hepatitis: evidence for IgG1 subclass restriction, polyclonality and non cross-reactivity with hepatocyte surface antigens.  Clin Exp Immunol. 1987;  69 543-549
    PubMedGoogle Scholar
  • 31 Lohr H F, Schlaak J F, Lohse A W et al.. Autoreactive CD4 + LKM-specific and anticlonotypic T cell responses in LKM-1 antibody-positive autoimmune hepatitis.  Hepatology. 1996;  24 1416-1421
    PubMedGoogle Scholar
  • 32 Battaglia M, Gregori S, Bacchetta R, Roncarolo M G. Tr1 cells: from discovery to their clinical application.  Semin Immunol. 2006;  18 120-127
    CrossrefPubMedGoogle Scholar
  • 33 Lohr H, Manns M, Kyriatsoulis A et al.. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis.  Clin Exp Immunol. 1991;  84 297-302
    PubMedGoogle Scholar
  • 34 Longhi M S, Hussain M J, Bogdanos D P et al.. Cytochrome P450IID6-specific effector CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2.  Hepatology. 2007;  , In press
    PubMedGoogle Scholar
  • 35 Matsumura S, Kita H, He X S et al.. Comprehensive mapping of HLA-A0201-restricted CD8 T cell epitopes on PDC-E2 in primary biliary cirrhosis.  Hepatology. 2002;  36 1125-1134
    CrossrefPubMedGoogle Scholar
  • 36 Reijonen H, Elliott J F, van Endert P, Nepom G. Differential presentation of glutamic acid decarboxylase 65 (GAD65) T cell epitopes among HLA-DRB1*0401-positive individuals.  J Immunol. 1999;  163 1674-1681
    PubMedGoogle Scholar
  • 37 Trotter J L, Pelfrey C M, Trotter A L et al.. T cell recognition of myelin proteolipid protein and myelin proteolipid protein peptides in the peripheral blood of multiple sclerosis and control subjects.  J Neuroimmunol. 1998;  84 172-178
    CrossrefPubMedGoogle Scholar
  • 38 Kita H, Matsumura S, He X S et al.. Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.  J Clin Invest. 2002;  109 1231-1240
    CrossrefPubMedGoogle Scholar
  • 39 Roth E, Pircher H. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.  J Immunol. 2004;  172 1588-1594
    PubMedGoogle Scholar
  • 40 Guy C S, Wang J, Michalak T I. Hepatocytes as cytotoxic effector cells can induce cell death by CD95 ligand-mediated pathway.  Hepatology. 2006;  43 1231-1240
    CrossrefPubMedGoogle Scholar
  • 41 Ando K, Moriyama T, Guidotti L G et al.. Mechanisms of class I restricted immunopathology: a transgenic mouse model of fulminant hepatitis.  J Exp Med. 1993;  178 1541-1554
    CrossrefPubMedGoogle Scholar
  • 42 Vergani D. LKM antibody: getting in some target practice.  Gut. 2000;  46 449-450
    CrossrefPubMedGoogle Scholar
  • 43 Pileri P, Uematsu Y, Campagnoli S et al.. Binding of hepatitis C virus to CD81.  Science. 1998;  282 938-941
    CrossrefPubMedGoogle Scholar
  • 44 Levy S, Shoham T. The tetraspanin web modulates immune-signalling complexes.  Nat Rev Immunol. 2005;  5 136-148
    CrossrefPubMedGoogle Scholar
  • 45 Rosa D, Saletti G, De Gregorio E et al.. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders.  Proc Natl Acad Sci USA. 2005;  102 18544-18549
    CrossrefPubMedGoogle Scholar
  • 46 Pal S, Sullivan D G, Kim S et al.. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism.  Gastroenterology. 2006;  130 1107-1116
    CrossrefPubMedGoogle Scholar
  • 47 Dickson R C. Clinical manifestations of hepatitis C.  Clin Liver Dis. 1997;  1 569-585
    CrossrefPubMedGoogle Scholar
  • 48 Bellentani S, Tiribelli C, Saccoccio G et al.. Prevalence of chronic liver disease in the general population of northern Italy: the Dionysos Study.  Hepatology. 1994;  20 1442-1449
    CrossrefPubMedGoogle Scholar
  • 49 Lenzi M, Bellentani S, Saccoccio G et al.. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort.  Gut. 1999;  45 435-441
    PubMedGoogle Scholar
  • 50 Giostra F, Manzin A, Lenzi M et al.. Low hepatitis C viremia levels in patients with anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis.  J Hepatol. 1996;  25 433-438
    CrossrefPubMedGoogle Scholar
  • 51 Muratori L, Lenzi M, Cataleta M et al.. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C.  J Hepatol. 1994;  21 199-203
    CrossrefPubMedGoogle Scholar
  • 52 Todros L, Saracco G, Durazzo M et al.. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.  Hepatology. 1995;  22 1374-1378
    PubMedGoogle Scholar
  • 53 Muratori P, Czaja A J, Muratori L et al.. Evidence of a genetic basis for the different geographic occurrences of liver/kidney microsomal antibody type 1 in hepatitis C.  Dig Dis Sci. 2007;  52 179-184
    CrossrefPubMedGoogle Scholar
  • 54 Bogdanos D P, Lenzi M, Okamoto M et al.. Multiple viral/self immunological cross-reactivity in liver kidney microsomal antibody positive hepatitis C virus infected patients is associated with the possession of HLA b51.  Int J Immunopathol Pharmacol. 2004;  17 83-92
    PubMedGoogle Scholar
  • 55 Muratori L, Bogdanos D P, Muratori P et al.. Susceptibility to thyroid disorders in hepatitis C.  Clin Gastroenterol Hepatol. 2005;  3 595-603
    CrossrefPubMedGoogle Scholar
  • 56 Kerkar N, Hadzic N, Davies E T et al.. De-novo autoimmune hepatitis after liver transplantation.  Lancet. 1998;  351 409-413
    CrossrefPubMedGoogle Scholar
  • 57 Andries S, Casamayou L, Sempoux C et al.. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine.  Transplantation. 2001;  72 267-272
    CrossrefPubMedGoogle Scholar
  • 58 Gupta P, Hart J, Millis J M, Cronin D, Brady L. De novo hepatitis with autoimmune antibodies and atypical histology: a rare cause of late graft dysfunction after pediatric liver transplantation.  Transplantation. 2001;  71 664-668
    CrossrefPubMedGoogle Scholar
  • 59 Heneghan M A, Portmann B C, Norris S M et al.. Graft dysfunction mimicking autoimmune hepatitis following liver transplantation in adults.  Hepatology. 2001;  34 464-470
    CrossrefPubMedGoogle Scholar
  • 60 Hernandez H M, Kovarik P, Whitington P F, Alonso E M. Autoimmune hepatitis as a late complication of liver transplantation.  J Pediatr Gastroenterol Nutr. 2001;  32 131-136
    CrossrefPubMedGoogle Scholar
  • 61 Spada M, Bertani A, Sonzogni A et al.. A cause of late graft dysfunction after liver transplantation in children: de-novo autoimmune hepatitis.  Transplant Proc. 2001;  33 1747-1748
    CrossrefPubMedGoogle Scholar
  • 62 Dunn M J, Crisp S J, Rose M L, Taylor P M, Yacoub M H. Anti-endothelial antibodies and coronary artery disease after cardiac transplantation.  Lancet. 1992;  339 1566-1570
    CrossrefPubMedGoogle Scholar
  • 63 Dunn M J, Rose M L, Latif N et al.. Demonstration by western blotting of antiheart antibodies before and after cardiac transplantation.  Transplantation. 1991;  51 806-812
    PubMedGoogle Scholar
  • 64 Joyce S, Mathew J M, Flye M W, Mohanakumar T. A polymorphic human kidney-specific non-MHC alloantigen: its possible role in tissue-specific allograft immunity.  Transplantation. 1992;  53 1119-1127
    PubMedGoogle Scholar
  • 65 Dubel L, Farges O, Sato Y, Bismuth H. Development of anti-tissue antibodies in the rat liver transplant model.  Transplantation. 1998;  65 1135-1137
    CrossrefPubMedGoogle Scholar
  • 66 Fedoseyeva E V, Tam R C, Popov I A, Orr P L, Garovoy M R, Benichou G. Induction of T cell responses to a self-antigen following allotransplantation.  Transplantation. 1996;  61 679-683
    CrossrefPubMedGoogle Scholar
  • 67 Fedoseyeva E V, Zhang F, Orr P L, Levin D, Buncke H J, Benichou G. De novo autoimmunity to cardiac myosin after heart transplantation and its contribution to the rejection process.  J Immunol. 1999;  162 6836-6842
    PubMedGoogle Scholar
  • 68 Dubel L, Farges O, Johanet C, Sebagh M, Bismuth H. High incidence of antitissue antibodies in patients experiencing chronic liver allograft rejection.  Transplantation. 1998;  65 1072-1075
    CrossrefPubMedGoogle Scholar
  • 69 Salcedo M, Pons J A, Sousa J M et al.. De novo autoimmune hepatitis after liver transplantation.  J Hepatol. 2001;  34 49 , (Abstract)
    PubMedGoogle Scholar
  • 70 Evans H M, Kelly D A, McKiernan P J, Hubscher S. Progressive histological damage in liver allografts following pediatric liver transplantation.  Hepatology. 2006;  43 1109-1117
    CrossrefPubMedGoogle Scholar
  • 71 Salcedo M, Vaquero J, Banares R et al.. Response to steroids in de novo autoimmune hepatitis after liver transplantation.  Hepatology. 2002;  35 349-356
    CrossrefPubMedGoogle Scholar
  • 72 Bogdanos D P, Choudhuri K, Vergani D. Molecular mimicry and autoimmune liver disease: virtuous intentions, malign consequences.  Liver. 2001;  21 225-232
    CrossrefPubMedGoogle Scholar
  • 73 Gao E K, Lo D, Cheney R, Kanagawa O, Sprent J. Abnormal differentiation of thymocytes in mice treated with cyclosporin A.  Nature. 1988;  336 176-179
    CrossrefPubMedGoogle Scholar
  • 74 Bucy R P, Xu X Y, Li J, Huang G. Cyclosporin A-induced autoimmune disease in mice.  J Immunol. 1993;  151 1039-1050
    PubMedGoogle Scholar
  • 75 Wu D Y, Goldschneider I. Cyclosporin A-induced autologous graft-versus-host disease: a prototypical model of autoimmunity and active (dominant) tolerance coordinately induced by recent thymic emigrants.  J Immunol. 1999;  162 6926-6933
    PubMedGoogle Scholar
  • 76 Damoiseaux J G, Beijleveld L J, van Breda Vriesman P J. Multiple effects of cyclosporin A on the thymus in relation to T cell development and autoimmunity.  Clin Immunol Immunopathol. 1997;  82 197-202
    CrossrefPubMedGoogle Scholar
  • 77 Sakaguchi S, Sakaguchi N. Role of genetic factors in organ-specific autoimmune diseases induced by manipulating the thymus or T cells, and not self-antigens.  Rev Immunogenet. 2000;  2 147-153
    PubMedGoogle Scholar
  • 78 Aguilera I, Wichmann I, Sousa J M et al.. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation.  Clin Exp Immunol. 2001;  126 535-539
    CrossrefPubMedGoogle Scholar
  • 79 Aguilera I, Sousa J M, Gavilan F, Bernardos A, Wichmann I, Nunez-Roldan A. Glutathione S-transferase T1 mismatch constitutes a risk factor for de novo immune hepatitis after liver transplantation.  Liver Transpl. 2004;  10 1166-1172
    CrossrefPubMedGoogle Scholar
  • 80 Aguilera I, Wichmann I, Gentil M A, Gonzalez-Escribano F, Nunez-Roldan A. Alloimmune response against donor glutathione S-transferase T1 antigen in renal transplant recipients.  Am J Kidney Dis. 2005;  46 345-350
    CrossrefPubMedGoogle Scholar

Diego VerganiM.D. Ph.D. 

Institute of Liver Studies, King's College Hospital

Denmark Hill, London SE5 9RS, United Kingdom